Objective: Proton pump inhibitors (PPIs) are the most prescribed gastrointestinal system medications and are often prescribed together with other medications. This may lead to drug interactions. In our study, it was aimed to determine the possible interactions of PPIs. Material and Methods: This retrospective study was conducted between January 1, 2021 and March 31, 2021. A prescription review was conducted in a community pharmacy in İstanbul and potential drug interactions were evaluated using the Medscape and Lexicomp databases. Results: A total of 114 prescriptions were reviewed. The mean age of the patients was 55.1±14.8 years, and the mean duration of PPIs use was 5 months. It was determined that the one who prescribed PPIs the most was the family physician and it was prescribed most frequently with the indication of gastroesophageal reflux disease. The total number of interactions in the prescriptions was determined as 248 in the Medscape database and 295 in the Lexicomp database (p<0.05). Pantoprazole was found to be the most interacting PPIs in both databases. Levothyroxine was found to be the drug that interacted most with PPIs in both databases. Age and duration of PPIs use were found to be positively significantly correlated (p<0.05). Conclusion: In our study, the number of potential drug interactions in prescriptions containing PPIs was found to be high. We think that the possible interactions and duration of use of drugs used due to comorbid diseases should be considered in prescriptions containing PPIs.
Keywords: Proton pump inhibitors; drug interactions; clinical pharmacy; prescriptions
Amaç: Proton pompası inhibitörleri (PPI) en çok reçete edilen gastrointestinal sistem ilaçları olup, diğer ilaç gruplarıyla birlikte sıklıkla reçete edilmektedir. Bu durum, ilaç etkileşimlerine yol açabilmektedir. Çalışmamızda PPI ilaçlarının olası etkileşimlerinin belirlenmesi amaçlanmıştır. Gereç ve Yöntemler: Bu retrospektif çalışma 1 Ocak 2021 ile 31 Mart 2021 tarihleri arasında yapılmıştır. İstanbul'da bir serbest eczanede reçete incelemesi yapılmış ve ilaç etkileşimleri Medscape ve Lexicomp veri tabanları kullanılarak değerlendirilmiştir. Bulgular: Toplam 114 reçete gözden geçirilmiştir. Hastaların yaş ortalaması 55,1±14,8 yıl, ortalama PPI kullanım süresi 5 ay olarak tespit edilmiştir. En sık PPI yazan hekimin aile hekimi olduğu ve en sık gastroözofageal reflü hastalığı endikasyonu ile reçete edildiği belirlenmiştir. Reçetelerdeki toplam etkileşim sayısı Medscape veri tabanında 248, Lexicomp veri tabanında 295 olarak belirlenmiştir (p <0,05). Pantoprazol, her iki veritabanında da en çok etkileşime giren PPI olarak bulunmuştur. Levotiroksin, her iki veri tabanında da PPI'lar ile en çok etkileşime giren ilaç olarak bulunmuştur. PPI kullanım süresi ile yaş arasında pozitif yönde anlamlı bir ilişki bulunmuştur (p<0,05). Sonuç: Çalışmamızda PPI içeren reçetelerdeki ilaç etkileşimlerinin sayısı yüksek bulunmuştur. PPI içeren reçetelerde komorbid hastalıklar nedeniyle kullanılan ilaçların olası etkileşimlerinin ve kullanım sürelerinin dikkate alınması gerektiğini düşünüyoruz.
Anahtar Kelimeler: Proton pompa inhibitörleri; ilaç etkileşimleri; klinik eczacı; reçeteler
- Wolfe MM (author), Feldman M (section editor), Grover S (deputy editor). Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders. UpToDate 2022. Cited: April 4, 2022. [Link]
- Veettil SK, Sadoyu S, Bald EM, Chandran VP, Khuu SAT, Pitak P, et al. Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. Br J Clin Pharmacol. 2022;88(4):1551-66. [Crossref] [PubMed]
- Lu Y, Ramachandra ACV, Pham M, Tu YC, Cheng F. CuDDI: A CUDA-based application for extracting drug-drug interaction related substance terms from PubMed literature. Molecules. 2019;24(6):1081. [Crossref] [PubMed] [PMC]
- Mallhi TH, Sarriff A, Adnan AS, Khan YH, Qadir MI, Hamzah AA, et al. Effect of fruit/vegetable-drug interactions on CYP450, OATP and p-glycoprotein: a systematic review. Trop J Pharm Res. 2015;14(10):1927-35. [Crossref]
- Turshudzhyan A, Samuel S, Tawfik A, Tadros M. Rebuilding trust in proton pump inhibitor therapy. World J Gastroenterol. 2022;28(24):2667-79. [Crossref] [PubMed] [PMC]
- Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201-11. [Crossref] [PubMed] [PMC]
- Casciaro M, Navarra M, Inferrera G, Liotta M, Gangemi S, Minciullo PL. PPI adverse drugs reactions: a retrospective study. Clin Mol Allergy. 2019;17:1. [Crossref] [PubMed] [PMC]
- Patel D, Bertz R, Ren S, Boulton DW, Någård M. A systematic review of gastric acid-reducing agent-mediated drug-drug ınteractions with orally administered medications. Clin Pharmacokinet. 2020;59(4):447-62. [Crossref] [PubMed] [PMC]
- Cumhur H, Muratdağı G, İnci MB, Akar E, Karadeniz F, Sürmeli O, et al. Sakarya'daki aile hekimliği uygulamalarından elde edilen proton pompa inhibitörleri reçete verilerinin retrospektif olarak değerlendirilmesi [Retrospective evaluation of prescription data for proton pump inhibitors obtained from family medicine practices in Sakarya]. Journal of Human Rhythm. 2020:6(3):138-46. [Link]
- Al-Dosari BS, Binafeef BM, Alsolami SA. Prescribing pattern of proton pump inhibitors among patients admitted to medical ward at King Abdulaziz University Hospital, Jeddah, Saudi Arabia: A retrospective study. Saudi Med J. 2021;42(12):1313-9. [Crossref] [PubMed] [PMC]
- Syafhan NF, Augustine M, Ramadhani U, Hersunaryati Y. Proton-pump inhibitor use and potential drug interactions in outpatients. International Journal of Applied Pharmaceutics. 2018;10(1):358-63. [Crossref]
- Korayem GB, Alkanhal R, Almass R, Alkhunaizan S, Alharthi G, Bin Sheraim N, et al. Patients, prescribers, and institutional factors associated with inappropriate use of acid suppressive therapy in medical wards: an experience of a single-center in Saudi Arabia. Int J Gen Med. 2021;14:5079-89. [Crossref] [PubMed] [PMC]
- Damji SS, Rabbani SA, Rao PGM, Butt AR. Proton pump inhibitor use and appropriateness analysis: a snapshot from a secondary care hospital. Journal of Pharmaceutical Health Services Research. 2021;12(2):206-12. [Crossref]
- O'Mahony L, Yelverton E. Prescribing of proton pump inhibitors in an Irish general practice. Ir Med J. 2019;112(5):932. [PubMed]
- Cena C, Traina S, Parola B, Bo M, Fagiano R, Siviero C. Prescription of proton pump inhibitors in older adults with complex polytherapy. Eur J Hosp Pharm. 2020;27(6):341-5. [Crossref] [PubMed] [PMC]
- Asdaq SMB, ALbasha M, Almutairi A, Alyabisi R, Almuhaisni A, Faqihi R, et al. Use of proton pump inhibitors: An exploration of awareness, attitude and behavior of health care professionals of Riyadh, Saudi Arabia. Saudi Pharm J. 2021;29(7):713-8. [Crossref] [PubMed] [PMC]
- Puchon E, Goboova M, Vano I, Fazekas T, Javorova-Rihova Z, Kuzelova M. Medication-related factors associated with proton pump inhibitor prescription beyond official guidelines in older adults. Eur Geriatr Med. 2020;11(6):1051-61. [Crossref] [PubMed]
- Ayanoğlu S. İstanbul Kartal bölgesindeki bir eczaneye müracaat eden hastaların proton pompa inhibitörü kullanımının değerlendirilmesi [Yüksek lisans tezi]. İstanbul: İstanbul Medipol Üniversitesi; 2019. [Link]
- Ambizas EM, Etzel JV. Proton pump inhibitors: considerations with long-term use. US Pharm. 2017;42(7):4-7. [Link]
- Bertsche T, Pfaff J, Schiller P, Kaltschmidt J, Pruszydlo MG, Stremmel W, et al. Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med. 2010;36(4):665-72. [Crossref] [PubMed]
.: Process List